Assembly Biosciences, Inc. (NASDAQ:ASMB) Director William R. Ringo sold 1,000 shares of the stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $33.70, for a total transaction of $33,700.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Shares of Assembly Biosciences, Inc. (ASMB) opened at 31.20 on Wednesday. The firm has a 50-day moving average of $31.28 and a 200 day moving average of $25.26. The firm’s market capitalization is $541.76 million. Assembly Biosciences, Inc. has a 52 week low of $10.93 and a 52 week high of $36.31.
TRADEMARK VIOLATION NOTICE: “Assembly Biosciences, Inc. (ASMB) Director William R. Ringo Sells 1,000 Shares” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2017/10/18/assembly-biosciences-inc-asmb-director-william-r-ringo-sells-1000-shares.html.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Assembly Biosciences by 11.2% during the 1st quarter. Vanguard Group Inc. now owns 503,851 shares of the biopharmaceutical company’s stock worth $12,843,000 after acquiring an additional 50,615 shares in the last quarter. AXA acquired a new position in Assembly Biosciences during the 2nd quarter worth approximately $2,477,000. Lyon Street Capital LLC acquired a new position in Assembly Biosciences during the 1st quarter worth approximately $767,000. JPMorgan Chase & Co. acquired a new position in Assembly Biosciences during the 2nd quarter worth approximately $3,426,000. Finally, Geode Capital Management LLC grew its holdings in Assembly Biosciences by 32.3% during the 1st quarter. Geode Capital Management LLC now owns 97,964 shares of the biopharmaceutical company’s stock worth $2,497,000 after acquiring an additional 23,926 shares in the last quarter. Institutional investors own 72.27% of the company’s stock.
A number of research firms have recently issued reports on ASMB. Chardan Capital reiterated a “buy” rating on shares of Assembly Biosciences in a research note on Sunday, September 17th. BidaskClub upgraded shares of Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 3rd. Finally, Zacks Investment Research upgraded shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.